Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 577 | 111 | 456 |
| Samples | 539 | 100 | 429 |
| Peptides | 294 | 68 | 248 |
Function
RBMXL2 · RBMX like 2
This gene belongs to the HNRPG subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs). The hnRNPs are RNA binding proteins and they complex with heterogeneous nuclear RNA (hnRNA). These proteins are associated with pre-mRNAs in the nucleus and appear to influence pre-mRNA processing and other aspects of mRNA metabolism and transport. While all of the hnRNPs are present in the nucleus, some seem to shuttle between the nucleus and the cytoplasm. The hnRNP proteins have distinct nucleic acid binding properties. The protein encoded by this gene has two RRM domains that bind RNAs. This gene is intronless and is thought to be derived from a processed retroposon. However, unlike many retroposon-derived genes, this gene is not a pseudogene. The encoded protein has similarity to HNRPG and RBMY proteins and it is suggested to replace HNRPG protein function during meiotic prophase or act as a germ cell-specific splicing regulator. It primarily localizes to the nuclei of meiotic spermatocytes. This gene is a candidate for autosomal male infertility. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000306904 | O75526 | 577 | 294 |
Gene Properties
Recurrent Mutations
All 294 amino-acid changes on canonical ENST00000306904 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RBMXL2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RBMXL2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Other Solid Cancers | 2/94 2% | 101/1515 7% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Melanoma | 9/210 4% | 64/1899 3% |
| Endometrial Carcinoma | 5/42 12% | 9/612 1% |
| Colorectal Carcinoma | 11/143 8% | 61/3239 2% |
| Gastric Carcinoma | 2/74 3% | 37/1809 2% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 19/1390 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Burkitts Lymphoma | 4/32 12% | 0/196 0% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 5/810 1% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 26/2550 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Neuroendocrine Tumour | 2/154 1% | 5/577 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Other Sarcomas | 2/69 3% | 4/699 1% |
| Head and Neck Carcinoma | 1/85 1% | 11/1574 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Ovarian Carcinoma | 7/109 6% | 0/998 0% |
| Biliary Tract Carcinoma | 0/54 0% | 6/950 1% |
| Non-Cancerous | 2/104 2% | 3/830 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| B-Cell Non-Hodgkins Lymphoma | 7/88 8% | 6/2534 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Glioma | 1/52 2% | 9/2127 0% |
| Hepatocellular Carcinoma | 4/46 9% | 6/2210 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
Mutation Distribution
Where RBMXL2 is mutated · all tissues, split by cell line vs tissue
How many mutations in RBMXL2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 45 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 577 mutations in RBMXL2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|